ArticleJournal of the American Pharmacists Association : JAPhA
Analysis of patient-specific factors contributing to effectiveness of glucagon-like peptide-1 receptor agonists.
Article in Journal of the American Pharmacists Association : JAPhA. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundGlucagon-like peptide-1 receptor (GLP-1) agonists are antidiabetic medications used to improve hemoglobin A1c (HbA1c) and promote weight loss. Per the Veterans Affairs/Department of Defense guidelines for the management of type 2 diabetes, GLP-1 agonists are expected to lower HbA1c by 1%-1.5%. The clinical pharmacy specialist in the women's health primary care clinic at the Louis A. Johnson Veterans Affairs Medical Center noted cases of women started on GLP-1 agonists achieving greater than expected HbA1c reduction.
objectivesThe primary objective of this study was to determine if there are any patient-specific factors that may increase the effectiveness of GLP-1 agonists. Secondary objectives included an analysis of average weight and HbA1c, use of the Pearson rank correlation test to determine if there is a correlation between weight change and HbA1c reduction, and an analysis of HbA1c reduction associated with each GLP-1 agonist prescribed.
methodsA retrospective chart review was conducted. Data collected from the charts included age, sex, height, GLP-1 agonist prescribed, and HbA1c and weight before and after GLP-1 agonist initiation. For primary outcomes, statistical analyses were run between 2 groups: patients who had an HbA1c reduction of greater than 1.5% and patients who had an HbA1c reduction less than or equal to 1.5%.
resultsWomen were more likely to have an HbA1c reduction of greater than 1.5% (P = 0.001). Patients with a lower baseline weight were more likely to attain an HbA1c reduction greater than 1.5% (P = 0.045). Higher baseline HbA1c was correlated with an increased likelihood of HbA1c reduction greater than 1.5% (P = 0.001).
conclusionGLP-1 agonists may be more effective at reducing HbA1c in female patients, those with a lower baseline weight, and those with a higher baseline HbA1c.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.